ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma-Reference-Cited by-同舟云学术

ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

Published:2021-11-29 Issue:12 Volume:2 Page:1372-1386
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Arrieta Víctor A.,Chen Andrew X.,Kane J. Robert,Kang Seong Jae,Kassab Cynthia,Dmello Crismita,Zhao Junfei,Burdett Kirsten B.,Upadhyayula Pavan S.,Lee-Chang Catalina,Shilati Joseph,Jaishankar Dinesh,Chen Li,Gould Andrew,Zhang Daniel^ORCID,Yuan Jinzhou,Zhao Wenting,Ling Xiaoyang,Burks Jared K.^ORCID,Laffleur Brice^ORCID,Amidei Christina,Bruce Jeffrey N.^ORCID,Lukas Rimas V.,Yamaguchi Jonathan T.,Cieremans David,Rothschild Gerson,Basu Uttiya^ORCID,McCord Matthew,Brat Daniel J.,Zhang Hui,Cooper Lee A. D.^ORCID,Zhang Bin,Sims Peter,Cloughesy Tim F.^ORCID,Prins Robert^ORCID,Canoll Peter,Stupp Roger,Heimberger Amy B.^ORCID,Horbinski Craig^ORCID,Iwamoto Fabio M.^ORCID,Rabadan Raul^ORCID,Sonabend Adam M.^ORCID

Funder

Consejo Nacional de Ciencia y Tecnología

U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases

U.S. Department of Health & Human Services | NIH | NIH Office of the Director

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link